Oliceridine fumarate in Anesthesia: NCT07372209 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Not Applicable
Clinical phase
Completed
Recruitment status
120
Planned enrollment
2025-12-15
Primary-completion proxy
Executive view
NCT07372209 evaluates Oliceridine fumarate in Anesthesia. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is blood pressure, assessed over baseline, at the moment of intubation, right after intubation, 1 minute、3 minutes, and 5 minutes after intubation.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07372209 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Anesthesia landscape. Drug & Asset MCP drug_fetch was queried for Oliceridine fumarate, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07372209 | Oliceridine fumarate | Not Applicable / Completed | Sponsor not reported | China | blood pressure baseline, at the moment of intubation, right after intubation, 1 minu… | 2025-12-15 |
| NCT07470853 | HWK-016 | Phase 1 / Recruiting | Whitehawk Therapeutics, Inc. | United States | Determine Maximum Tolerated Dose (MTD) From Cycle 1, Day 1 Until Cycle 1, Day 21 (21-day cycles) | 2028-02-01 |
| NCT07462663 | GLP-1 agonist (Nxera Pharma) | Phase 4 / Not yet recruiting | Bellvitge University Hospital | Geography not reported | Recruitment Rate From study opening to end of recruitment, up to 36 months. | 2031-04-01 |
| NCT07453394 | Olaparib | Phase 1/2 / Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Geography not reported | Incidence and severity of adverse events up to 2 years | 2027-04-01 |
| NCT07444814 | HWK-007 | Phase 1 / Recruiting | Whitehawk Therapeutics, Inc. | United States | Determine Maximum Tolerated Dose (MTD) From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles) | 2028-10-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07372209 is a Not Applicable, completed study with 120 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.
The primary endpoint is “blood pressure” over “baseline, at the moment of intubation, right after intubation, 1 minute、3 minutes, and 5 minutes after intubation.” No additional primary-endpoint description was returned in the selected field set.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 120 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Sufentanil Citrate as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Anesthesia. These records do not establish direct evidence for NCT07372209 unless the registration number matches.
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhib…
Phase 1/2; n=97; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 62 Participants ; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05572684
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase 2; n=62; CBR = 27 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01797523
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given…
Phase 1/2; n=19; Number of Participants With DLTs in Each Module = 0 Participants ; Number of Participants With DLTs in Each Module = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05714553
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Oliceridine fumarate is indexed as Small molecule drug with μ opioid receptor biology and a global stage of Approved. The asset profile lists Trevena, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Oliceridine fumarate is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07372209
Protocol source: https://clinicaltrials.gov/study/NCT07372209
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
Oliceridine fumarate in Anesthesia is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes blood pressure and 2025-12-15 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
